Vensica is developing minimally invasive solutions in urology, using the unique properties of therapeutic ultrasound to deliver Botulinum Toxin A
Botulinum Toxin A is highly efficacious in several bladder indications, including Overactive Bladder, Neurogenic Bladder, and Painful Bladder Syndrome. However, the toxin is currently injected into the bladder wall in an invasive procedure that involves side effects, pain and anesthesia.
Bladder cancer: in addition to toxin delivery, Vensica is also working to improve bladder cancer treatment with its proprietary platform.
Vensica developed a proprietary minimally invasive, needle-free device to deliver botulinum toxin A to the bladder. Vensica’s procedure is very simple and quick both for the urologist and the patient.
No needles, no anesthesia, and no cystoscopy required.
Overactive Bladder: Over 4 million patients fail oral medication treatment and seek a non-invasive solution to their illness.
Neurogenic Bladder: Over 1.5 million patients do not respond positively to oral medication treatment and seek a non-invasive solution to their illness.
Painful Bladder Syndrome: No effective treatment available for the 2 million patients in the USA.
A serial entrepreneur with background from Yale BSc and Technion MSc
Extensive experience in leading start ups from inception to go-to-market. Technion MSc, System Engineering.
Sign up to hear from us